DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
OpenAI Restricts Astra AI Over Cyberattack Risks 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
TUSTIN, Calif., March 05, 2018 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the third quarter of fiscal year 2018 ended January 31, 2018 on March 12, 2018 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Avid's senior management will discuss financial results for the third quarter and review recent corporate developments.
To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/events.cfm.
To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Avid Bioservices call.
About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With nearly 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. www.avidbio.com
Contacts: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]
